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INTRODUCTION 


Peptic ulcer disease is one of the most common disease  affecting 
the general population. Although morbidity exceeds the mortality by 
several times, the health costs due to the disease is increasing inspite of 
advances in treatment and ever increasing awareness about the disease 
due to the high recurrence rate of the disease. 
 
 
The good old adage “No acid, no ulcer” holds good even today. 
With excellent advances in medical control of acid secretion with proton 
pump inhibitors the incidence of disease has gone down. But  the 
prevalence of the disease is ever increasing due to high recurrence rate 
after cessation of acid controlling therapy. 
 
 
The discovery by MARSHALL and WARREN that the human 
gastric mucosa is colonized by a spiral gram negative organism 
Helicobacter pylori and its association with producing and causing 
recurrence of disease after adequate control of disease has opened up 
newer concept of conquering of a disease by mankind. 
 The silver lining in this that Helicobacter pylori infection can be 
controlled adequately with proper and adequate medical therapy has 
made possible for man to assert his supremacy once again. 
 
 
The incidence of Helicobacter pylori is high in developing 
countries. There has been a reported decrease in prevalence in developed 
countries due to improved living conditions. 
 
 
Poor socioeconomic status, poor hygiene and close personal 
contact are closely linked with its high prevalence. 
 
 
Hence in a country like India where every penny counts, it is worth 
to treat the basic cause and keep the population disease free which in turn 
means good work force and also reduce the health expenditure on this 
disease. 
 
 
With this background the current study is intended to study the 
relationship between Helicobacter pylori infection and duodenal ulcer in 
our hospital population. 
REVIEW OF LITERATURE


HISTORICAL REVIEW 
 
 In 18933 Bizzozero, an Italian pathologist reported a spiral 
bacteria in canine stomach. 
 In 1896 similar findings were reported in other animals by 
Saloman4 
 In 19065 the spiral bacteria were demonstrated in human stomach 
for the first time. 
 In 1938 Doeuges demonstrated spirochaetes in stomach of 
necropsy specimens. 
 In 1940 freedberg and Barrow used silver staining techniques to 
demonstrate spirochaetes in gastric mucosa. 
 Further investigations by Fitzgerald and Murphy demonstrated the 
occurrence of gastric spiral bacteria with urease  activity. This was 
further confirmed in gastrectomy specimens. 
 In 1968 bacterial source of urease was demonstrated by absence 
of urease activity in germ free stomach7. 
 1975 bacteria was associated with gastritis in 80% of resected 
specimen with gastric ulcer8. 
  1983 – 1987 
 
Robin Warren, histopathologist at Royal Perth hospital, 
Australia stained mucosal biopsy specimens with warthin starry 
stain and demonstrated the spiral bacteria11. 
 
Marshall treated a patient with gastritis and spiral bacterium 
with tetracycline and noted clearance of infection and 
improvement in symptoms9. 
 
Several attempts to culture these bacilli were  unsuccessful. 
Finally in April 1982 when the  culture  plates were left 
unintentionally to incubate for five days colonies appeared10. 
 
These camphylobacter like organisms (CLO) were named 
camphylobacter pyloridis since they were microaerobic, curved 
gram negative bacteria and resembled other camphylobacteria. 
 
 
 In 1987 it was changed to camphylobacteria pylori12. 
 
 In 1989 a new genus name was proposed and finally called as 
Helicobacter pylori13 
  Helicobacter pylori was described with the following features 
 
1. Cell motility by means of sheathed flagella 
 
2. An external glycocalyx produced invitro in liquid media 
 
3. Menaquinone E (Me - E) present as the major isoprenoid 
quinone 
4. G + C content of chromosomal DNA of 35-44% 
KEY NOTES IN HISTORY 
                   OF HELICOBACTER PYLORI 
1893 - gastric spiral bacteria reported in animals14 
1906 - spirochaetes demonstrated in human stomach15 
1924 - urease activity reported in stomach16 
1975 - Gastric spirochaetes and gastritis present in 80% of gastric 
ulcers18. 
1983 - CLO associated with gastritis and possibly peptic ulceration19 
1985 - Temporal relationship between acquisition of helicobacter  
pylori infection and development of gastritis20 
1987 - Eradication of helicobacter pylori leads to long term cure of 
duodenal ulceration21 
1989 - Genus helicobacter formed22 
 
1991  - Relationship between the organism and gastric adeno 
carcinoma and MALT lymphoma reported23. 
1994  - Helicobacter pylori classified as Grade I (definitive) 
carcinogen24 
EPIDEMIOLOGY

 Human beings are the major reservoir of Helicobacter pylori 
 
 
 Distribution of Helicobacter pylori is world wide26 
 
 Most commonly the infection is acquired during childhood27 
 
 The prevalence of infection increases with age from 10% at age 
10 to 60% at age 60 in developed countries 
 
 In developing countries upto 100% of children are infected by 
the age of 10 years28. 
 
 Adults rarely become infected with seroconversion rates 
between 0.33 – 05% per person per year29. 
 
 Prevalence of infection in poor socio economic status is high28. 
 
 Poor hygiene, close personal contact and over crowding are 
known risk factors for spread of Helicobacter pylori28 
 
 Human milk IGA is protective for infants from Helicobacter 
pylori infection. This protection was demonstrable only upto 9 
months. 
  No difference in seroconversion rate between males  and 
females. 
 
 Increased helicobacter pylori seropositivity has been seen ion 
gastroenterologists and endoscopists31. 
 
 Submariners showed a higher rates of helicobacter pylori 
seropositivity than in other military comparison groups32. 
 
 Several studies found no increased risk of infection in dentists33. 
 ELECTRON MICROSCOPIC PICTURE OF 
HELICOBACTER PYLORI 
 
 
 
 
MRPHOLOGY


GENUS HELICOBACTER 
SPECIES PYLORI 
 It is a gram negative spiral bacillus 
 
 It is unipolar, multiflagellate numbering around  40.  The  flagella 
of Helicobacter pylori are sheathed with a covering that is 
continuous with the outer membrane components of the body 
wall. 
 It is three microns in length 0.5 to 1 milli microns in diamater. 
 
 
 
ULTRA STRUCTURAL FEATURES 
 
 Electron microscopy reveals the presence of 40 mm thick 
glycocalyx or capsule like polysaccharide rich layer outer to cell 
membrane. 
 
 
PHYSIOLOGICAL PROPERTIES 
 
 Helicobacter pylori is microaerophile growing best in an 
atmosphere of 5% oxygen with 5-10% CO2 on blood containing 
media. 
 Eg. Oxoid brain heart infusion agar 
 
5% blood agar enriched with 1% isovitale x. 
Enriched chocolate agar broth. 
It appears as translucent, circular, convex, colonies 
of about 2 millimeter in diameter. 
 
 
BIOCHEMICAL CHARACTERISTICS 
 
 Helicobacter pylori produces 
 
 Catalase 
 
 Cytochrome oxidase 
 
 Protease 
 
 Phospholipase A2 C 
 
 Acid phosphatase 
 
 Alkaline phosphatase 
 
 Leonine arylamidase 
 
 Naphthol AS-B1 phosphohydrolase 
 
 Esterases C4, C8 
 
 Gammaglutamyl transpeptidase 
 
 
 
It produces urease which is present in the cytoplasm and surface 
of the organism. 
 Urease produces the following action 
 
 
 
 
 
Ammonium formed creates an alkaline environment around the 
organism which protects the organism from the gastric acid assault 
enhancing survival. 
 
 
GENOMIC DNA 
 
It is a single circular molecule with a mean size of 1.71 Mb 
ranging from 1.40   1.73 Mb and base composition in the range    35 – 
37 mol % G + C. 
 
 
FATTY ACID COMPOSITION 
 
The major cellular fatty acids are tetradeconoic acid and is 11, 
 
12 methylene octadecanoic acid with smaller amounts of 
hexadeconoic acid and 3 hydroxy decanoic acid. 
 
 
The main respiratory quinone is menaquinone - 6 (MK - 6) 
Urea + H+ + water urease bicarbonate + ammonium 
 
C = O(NH2)2 + H+ + 2H2O urease HCo3 + 2(NH4) 
 Extrachromosomal DNA plasmid DNA is present in 45% of 
strains. 
 
 
The lipopolysaccharide part of Helicobacter pylori  express  lewis 
x and y blood group antigens in 80% strains which are not found in other 
gram negative organisms. 


The natural habitat of helicobacter pylori is human stomach. 
 
Any part of the stomach may become colonized but the mucus 
secreting epithelium of the antrum is the favoured site. 
Colonization of areas of gastric metaplasia or ectopic gastric 
mucosa in other parts of the gastrointestinal track. 
Helicobacter pylori has been detected in dental plaque by 
cultured. 
It has also been cultured from saliva of a patient with gastritis. 
 
 
 
Survival in gastric mucosa 
 
It lives beneath the mucus layer that covers the gastric mucosa. 
It lies deep inside the crypts of gastric glands. 
Spiral shape and motility makes it able to resist peristalsis. 
 
Urease produces a protective alkaline environment around the 
organisms. This buffers the acid assault. 
Microaerophilic nature is suited for the environment and 
adhesions help in permanent residency. 
Protease produced by helicobacter pylori helps to establish itself 
in this stomach wall bypassing localized inflammation. 
MODE OF TRANSMISSION

Potential mode of transmission is by three ways 
 
 
 
1. FAECO ORAL TRANSMISSION 
 
Water has been a source of Helicobacter pylori infection. The 
organism has been isolated from faeces34. Polymerase chain reaction 
assays have demonstrated the presence of organism in food and drinking 
water. 
 
 
2. ORAL - ORAL TRANSMISSION 
 
Helicobacter pylori has been isolated from the oral  cavity.  There 
is evidence of transmission between spouses although it could  be due to 
common source infection35. It is also possible that re- infection may 
occur by person to person transmission between spouses36. 
 3. GASTRO ORAL TRANSMISSION 
 
In children it may be due to reflux and vomiting. A physician 
become infected with Helicobacter pylori after he gave mouth to  mouth 
resuscitation to a patients with positive Helicobacter pylori status who 
had recently vomited37. 
 
Another important source is iatrogenic transmission in individuals 
who have undergone endoscopy procedures with a contaminated pH 
electrode or biopsy forceps. 
PATHOGENESIS

Helicobacter pylori is the main cause of duodenal and gastric 
ulceration. It is also a major risk factor for adenocarcinoma and 
lympoma. 
 
Development of the disease is influenced by 
 
1. Virulence of the infecting strain 
 
2. genetic susceptibility of the host 
 
3. Environmental co-factors 
 
 
 
1. VIRULENCE FACTORS 
 
A host of factors contribute to the ability of Helicobacter pylori to 
colonize gastric mucosa, evade host defences and damage host tissue. 
 
 
Helicobacter pylori localizes on epithelial surface beneath the 
mucous layer. 
It attaches to epithelial cells by adhesin. 
It can also invade the epithelial cells, 
 It produces a cytotoxin which is vacuolising. 
 
It contains cytotoxin associated gene A (“Cag” segment of 
DNA). 
 
 
Damage is caused by 
 
 reduced epithelial cell turnover
 
 reduced surface hydrophobicity
 
 increased lipolysis
 
 release of chemotactic factors
 
 activation of classical complement pathway
 
 stimulation of G cells
 
 
 
Other factors include 
 
Adhesins, protease, lipase, catalase, superoxide dismutase and 
platelet activating factor. 
 
 
Host factors 
 
 Host HLA type39 
 
 Blood group antigen type40 
Environmental factors30 
 
 Living conditions particularly in childhood since most of the 
infections are acquired in childhood. 
 Smoking 
 
 Dietary factors 
 
 
 
Gastric colonization is a pre requisite for Helicobacter pylori 
associated disease. For this both urease and motility are vital. 
 
 
Infection is lifelong unless eradication treatment is given. This 
indicates that Helicobacter pylori evades host immune defences 
effectively. 
 
 
Gastric inflammation in Helicobacter pylori infected individuals 
represents the host immune response to the organism43. 
 
Gastritis caused by Helicobacter pylori is characterized by surface 
epithelial degeneration, infiltration of mucosa by chronic inflammatory 
cells (lymphocytes, plasma cells and occasional eosinophils) and 
neutrophils. 
 The effect of gastritis on gastric acid secretion depends upon to 
what extent it involves the antrum or body mucosa. 
 
 
Gastritis confined to antrum without atrophy results in 
hypersecretion of acid. This is due to stimulated increased release of 
gastrin42. This is the pattern of gastritis seen in individuals with duodenal 
ulceration41. 
 
Now it is proved that increased gastric release is due to deficient 
somatostatin. 
 
 
Helicobacter pylori infected patients have significantly higher 
basal. 24 hours meal stimulated and gastrin releasing peptide  stimulated 
gastrin levels than normal individuals 
 
 
Basal and gastrin releasing peptide stimulated acid secretion are 
increased only in symptomatic individuals as compared to asymptomatic 
infected patients. 
 When the gastritis involves the mucosa of body then parietal cells 
are impaired by the inflammatory process.  There is no increase  in acid 
secretion. This will lead to hypochlorhydria or achlorhydria. 
 
 
Two types of metaplasia can occur in chronic gastritis 
 
1. Pyloric metaplasia 
 
There is replacement of the fundic type glands by 
mucus secreting glands. 
 
 
2. Intestinal metaplasia 
 
Progressive replacement of gastric mucosa by intestinal 
type epithelium of either small or large bowel type including 
goblet cells, absorptive cells (brush border), paneth cells and other 
endocrine cells44. 
CLINICAL ASSOCIATIONS

Helicobacter pylori has been implicated in the following disease26 
 
1. Duodenal ulcer 
 
2. Gastric ulcer 
 
3. Gastroduodenitis 
 
4. Carcinoma body and antrum 
 
5. MALT asso gastric lymphoma 
 
 
 
Extra intestinal manifestations 
 
1. Ischaemic heart disease 
 
2. Cerebro vascular accident 
 
3. Raynaud’s phenomenon 
 
4. Idiopathic migraine 
 
5. Henoch schonlein purpura 
 
6. Sjogren’s syndrome 
 
7. Autoimmune thrombocytopenia 
 
8. Extragastric MALT lymphomas 
 
9. Siderophenic anaemia 
10.Idiopathic chronic urticaria 
 11.Acne rosaceae 
12.Alopecia areata 
13.Cirrhosis 
14.Cholesterol stones 
15.Chronic cholecystitis 
16.Bronchictasis 
17. Sudden infant death syndrome 
18.Non ulcer dyspepsia 
 
 
 It is also present in asymptomatic normal gastric mucosa. 
 
 95% of patients with duodenal ulcers and 80% of patient with 
gastric ulcer are infected with the bacterium and its eradication 
greatly diminishes the recurrence rate. 
 Evidence in support of Helicobacter pylori as a causative agent in 
peptic ulcer disease 
 
 
1. Follow up of the natural history of the subjects infected 
with Helicobacter pylori revealed 11% developed peptic 
ulcers compared with less than 1% of subjects without 
gastritis45. 
 2. World wide consistent association of Helicobacter pylori 
and ulcer disease46. 
 
3. Multiple prospective treatment trials indicate that the 
eradication of Helicobacter pylori prevents recurrent 
duodenal ulcer in most cases47. 
 
4. The effects of the infection were illustrated after  deliberate 
ingestion of a suspension of the organism (Koch’s 
postulate)20. 
DIAGNOSTIC METHODS 
These can be divided into 
 
1. those requiring endoscopy 
 
2. those not requiring endoscopy 
 
 
 
These can also be divided into those done for initial diagnosis 
(pre treatment) and for assessment of cure (post treatment). 
 
 
Method involving endoscopy 
 
The critical role of endoscopy in the diagnosis of helicobacter 
pylori is to obtain gastric mucosal biopsies which are utilized for both 
direct and indirect methods of detecting the presence of organism. 
 
 
1. Direct method are 
 
a. Culture and 
 
b. Histology 
 
 
 
2. Indirect methods 
 
a. Urease testing 
 GIEMSA STAINING OF HELICOBACTER 
PYLORI 
 
 
 
 
 
 
 They can also be divided into 
 
Invasive Noninvasive 
 
1. Urease 1. Serology 
 
2. Culture 2. Urea breath test 
 
3. Histology 
 
4. PCR 
 
 
 
1. CULTURE 
 
This is not routinely done. 
 
Sensitivity achieved is more than 95% in some series. It takes 2-
5 days time. Antibiotic sensitivity can be determined. 
It must be incubated at 370C under high humidity for a  
maximum of 24 - 72 hours. 
 
 
2. HISTOLOGY 
 
This is the Gold Standard for the diagnosis of Helicobacter 
pylori on gastric biopsies. 
Needs reasonably large bits for study. 
 
Prepyloric antrum has been the preferred site of biopsy. 
 Staining methods in use are 
 
1. GIEMSA 
 
2. Eosin and haematoxylin 
 
3. Warthin starry silver stain 
 
 
 
3. RAPID UREASE TEST (RUT) 
 
Developed by Marshall. CLO test is the first commercially 
available test. 
 
 
Helicobacter pylori urease hydrolysis the urea contained in the 
agar gel of the test solution to produce ammonia.  This causes a pH  rise 
and change of colour from yellow to pink. 
 
 
Phenol red is used as indicator. 
 
The test is interpreted upto 24 hrs after inoculating the biopsy 
specimen. 
The overall sensitivity of the test was 90%48. 
 
 
The other commercially available RUT are 
 
1. Hp test 
 
2. Pyloritek - strip test 
 4. POLYMERASE CHAIN REACTION 
 
It is currently done for research purposes to identify different 
strains. 
5. ANTIBODY DETECTION 
 
Helicobacter pylori IgG antibodies are detected by 
 
1. ELISA 
 
2. Latex agglutination test 
 
 
 
They are non-invasive and inexpensive tests 
 
It is a reasonable choice for initial diagnosis of helicobacter 
pylori infection. 
 
 
6. UREA BREATH TEST 
 
13
C and 14C urea breath test measures the activity of 
Helicobacter pylori urease. 
 
 
Oral radioactive carbon labeled urea is given. If Helicobacter 
pylori is present in the stomach, urease hydrolyses the labeled urea 
releasing labeled bicarbonate that is transported in the blood to the lungs 
and enhaled as carbondi-oxide. 
 The breath is collected and radioactivity level is measured. This 
test is done in children. 
 
 
This test should not be used in patients who have taken proton 
pump inhibitors, bismuth compounds or antibiotics. 
 
 
Other assays 
 
1. Detection of antibodies in urine. 
 
2. measurement of labelled serum bicarbonate following 
administration of radioactive labeled carbon. 
3. Measurement of radioactivity in urine. 
 
4. Measurement of 15N labeled ammonia which is absorbed and 
excreted in the urine. 
 
 
POST TREATMENT TEST 
INDICATIONS 
1. Patients with bleeding duodenal ulcer on completion of 
eradication therapy. 
2. Patients with recurrent peptic ulcer symptoms. 
 Routine testing is not advocated in patients with uncomplicated 
duodenal ulcer. 
This test should be performed ideally four weeks after 
completion of eradication therapy. 
TREATMENT 


The aim of treatment is to eradicate Helicobacter pylori. 
Eradication is defined as negative tests for Helicobacter pylori atleast 28 
days after the end of antimicrobial therapy. 
 
 
Ideal therapy for Helicobacter pylori should be 
 
 Simple 
 
 Safe 
 
 free from side effects 
 
 efficacy is 100% 
 
 low cost 
 
 acceptable to the patient 
 
 available to the patient 
 
 
 
Therapies available 
 
1. Dual therapy 
 
2. Triple therapy 
 
3. Low dose triple therapy 
 
4. Quadruple therapy 
 DUAL THERAPY 
 
Table No. 1 
 
Drug Dose Duration Eradication 
Omeprazole 
 
Amoxycillin 
20 - 40 mg BD 
 
750 mg TDS 
2 wks 50 – 85 % 
 
Table No. 2 
 
Drug Dose Duration Eradication 
Ranitidine bismuth citrate 
 
Amoxycillin 
400 - 500 mg BD 
 
500 mg QID 
2 wks 65 % 
 
 
Table No. 3 
 
Drug Dose Duration Eradication 
Omeprazole 
 
Clarithromycin 
40 mg OD 
 
500 mg TID 
2 wks 80 %49 
 
 
Table No. 4 
 
Drug Dose Duration Eradication 
Ranitidine bismuth citrate 
 
Clarithromycin 
400 mg BD 
 
500 mg BD 
2 wks 80%50 
 TRIPLE THERAPY 
 
Table No. 5 
 
Drug Dose Duration Eradication 
Omeprazole 
Amoxycillin 
Metronidazole 
40 mg OD 
 
500 mg TID 
 
400 mg TID 
7 days 95 % 
 
 
Table No. 6 
 
Drug Dose Duration Eradication 
Ranitidine 
Amoxycillin 
Metronidazole 
300 mg OD 
 
750 mg TID 
 
500 mg TID 
12 days 90 % 
 Table - 7 
LOW DOSE TRIPLE THERAPY 
Drug Dose Duration Eradication 
PPI 
Clarithromycin 
Metronidazole 
20 mg OD or BD 
250 mg BD 
400 mg BD 
7 days 90 % 
 
 
Table - 8 
LOW DOSE TRIPLE THERAPY 
Drug Dose Duration Eradication 
PPI 
Clarithromycin 
Metronidazole 
20 mg BD 
 
1 gm BD 
 
250 - 500 mg BD 
7 days 90 % 
 Table - 9 
 
QUADRUPLE THERAPY 
 
Drug Dose Duration Eradication 
PPI 20 mg OD or BD 7 days 85 - 95 % 
Colloidal bismuth citrate 120 mg QID 
  
Tetracycline 500 mg QID 
  
Metronidazole 400 mg TID 
  
 
Low dose triple therapy is the most preferred therapeutic regimen. 
It results in a high eradication rate and most economical regimen51. 
 
Clarithromycin based drug regimens achieved a  good eradication 
rate with a definitive advantage is smokers54. 
 
Quadruple drug regimen using bismuth with two antibiotics and 
proton pump inhibitors does not seen to offer any additional 
advantages55. 
AIM OF STUDY

A random group of adult male and female patients who had 
epigastric pain were group to formulate this study aiming at 
1. To find out the incidence of Helicobacter pylori in proven cases 
of duodenal ulcer. 
 
 
2. To find out the association of Helicobacter pylori in individuals 
with normal upper gastrointestinal tract. 
 
 
3. To analyse the incidence of Helicobacter pylori with reference  
to 
1. Age 
 
2. Sex 
 
3. Socio economic status 
 
4. Symptoms 
 
5. Signs 
 
 
 
4. To compare with other studies 
MATERIALS AND METHODS 

DESIGN OF STUDY 
 
This is a case control study in detecting the prevalence of 
Helicobacter pylori among 50 patients with duodenal ulcer  and  another 
50 patients with normal upper gastrointestinal  tract  as controls. 
 
 
This study involves randomized controlled trials in which both the 
study group and control group were selected according to set selection 
criteria as detailed below. 
 
 
STUDY PERIOD 
 
The study was conducted from May 2005 to March 2006 in 
patients from around Coimbatore who were subjected to upper 
gastrointestinal endoscopy. 
 
 
STUDY CENTRE 
 
This study was carried out at Department of Surgery and 
Department of gastroenterology of Coimbatore Medical College 
Hospital, Coimbatore. 
 ENDOSCOPE AND BIOPSY FORCEPS 
 
 
 
 
 
 SUBJECT SELECTION 
 
Totally 100 patients were selected from those who had 
undergone upper gastro intestinal endoscopic evaluation. 
50 patients with duodenal ulcer were grouped as cases. 
 
50 patients with normal upper gastro intestinal endoscopy were 
grouped as controls. 
 
 
SELECTION CRITERIA 
 
 Endoscopically proved duodenal ulcer was made as an absolute 
pre requisite. 
 Patients above 12 yrs of age 
 
 No other obvious findings like gastric ulcer, baretts esophagus, 
oesophagitis in the endoscopy. 
 No history of previous NSAID ingestion 
 
 
 
TECHNIQUE 
 
Upper gastrointestinoscopy was performed under local 
anaesthesia after fully explaining the procedure to the patient. 
 
 
Patients were asked to lie in left lateral position with both hips 
and knee flexed and arms between the legs. 
 NORMAL DUODENAL MUCOSA 
 
 
 
 
 
DUODENAL ULCER 
 
 DUODENAL ULCER WITH PYLORIC STENOSIS 
 
DUODENAL ULCER WITH INFLAMMATORY 
CHANGES 
 
 
 A plastic mouth gag was inserted and held firmly by the assistant. 
 
 
Local anaesthetic spray was used before inserting the  endoscope. 
Endoscope was passed into the oropharynx crossing the cricopharynx 
into the oesophagus all the way encouraging the patient  to swallow. 
 
 
Once the tube has crossed the cricopharyngeal sphincter tube  can 
be easily passed without the patients aid. 
 
 
The oesophagus stomach, first and second part of the duodenum 
were visualized and screened for any pathology. 
 
 
If the patient was found to have a duodenal ulcer biopsy was taken 
from multiple sites in the antrum of stomach. 
Endoscope and biopsy forceps were disinfected. 
 
 
 
RAPID UREASE TEST 
 
Urea (10%) 10 gm 
Distilled water 100 ml 
 UREASE SOLUTION WITH BIOPSY BIT 
INOCULATED AND PHENOL RED ADDED 
 
 
UREASE TEST POSITIVE 
 
 Monobasic potassium dihydrogen phosphate 0.005 % 
Phenol red indicator 
Dissolved in distilled water 
Autoclave if for 30 minutes 
 
 
PROCEDURE 
 
1 ml liquid urease medium is dispensed in autoclaved bottles. 
Biopsy bits are inoculated in the endoscopy room and one drop of phenol 
red is added and observed for 30 mins to 1 hours. If there is colour change 
from yellow to pink it is considered positive. 
 
 
Fresh solutions are prepared every week. 
RESULTS 


The full collected details of cases and controls have been 
recorded in the master chart. 
 
 
This study is composed of 100 patients. 
 
- 50 patients with duodenal ulcer 
 
- 50 patients with normal gastrointestinal tract 
 
 
 
Age group included in the duodenal ulcer group and control 
group is between 15 – 80 yrs. 
 
 
Sex distribution in the study is as follows 
 
 
 
In case out of 50 patients 35 were male and 15 were female 
 
 
 
Out of 50 controls 20 were male and 30 were female 
 
 
 
The following results and observations were arrived at after 
analyzing the collected data from this study. 
 Helicobacter pylori in duodenal ulcer and controls 
 
The prevalence of helicobacter pylori is high among duodenal 
ulcer patients (78%) when compared with controls (26%). 
 
 
The ratio of helicobacter pylori positive versus negative incidence 
in duodenal ulcer patients is 4 : 1. (Chart - 1). 
 
 
The ratio of helicobacter pylori positive versus negative incidence 
in controls is 1:3. (Chart - 2). 
PREVALENCE OF HELICOBACTER PYLORI 
 
Table No. 10 
 
 
 
Study Group 
 
 
Nos 
Helicobacter pylori 
 
+ve 
Helicobacter pylori 
 
-ve 
Nos % Nos % 
Duodenal ulcer 50 39 78% 11 22% 
Control 50 13 26% 37 74% 
 
 
The incidence of Helicobacter pylori in both duodenal ulcer 
patients and control group increases progressively from younger age 
group to older age group. 
  
 
 
 
PREVALENCE OF HELICOBACTER 
PYLORI 
 
 
 
 
 
 
 
 
 
 
 
78% 
 
 
Helicobacter Pylori Positive Helicobacter Pylori Negative 
26% 
 
 
 
 
 
 
74% 
 AGE GROUP DISTRIBUTION CHART FOR CASES 
Table No. 11 
 
 
S. 
No. 
Age 
(yrs) 
No. of 
cases 
H.P. 
+ve 
H.P. 
-ve 
% H.P. 
+ve 
H.P. 
-ve 
M F 
1 10-20 4 - 4 8 0 100 3 1 
2 21-30 8 6 2 16 75 25 5 3 
3 31-40 17 14 3 34 82 18 10 7 
4 41-50 7 6 1 14 86 14 6 1 
5 51-60 9 8 1 18 89 11 8 1 
6 61-70 3 3 - 6 100 0 2 1 
7 71-80 2 2 - 4 100 0 1 1 
 
 
AGE GROUP DISTRIBUTION CHART FOR CONTROLS 
Table No. 12 
 
 
S. 
No. 
Age 
(yrs) 
No. of 
cases 
H.P. 
+ve 
H.P. 
-ve 
% H.P. 
+ve 
H.P. 
-ve 
M F 
1 10-20 3 0 3 6 0 100 1 2 
2 21-30 10 1 9 20 10 90 4 6 
3 31-40 16 6 10 32 37.5 62.5 8 8 
4 41-50 13 4 9 26 31 69 4 9 
5 51-60 4 1 3 8 25 75 0 4 
6 61-70 2 1 1 4 50 50 1 1 
7 71-80 2 0 2 4 0 100 2 0 
 Cases 
10-20 21-30 31-40 41-50 51-60 61-70 71-80 
35 
30 
25 
20 
15 
10 
 
 
AGE GROUP DISTRIBUTION OF 
CHART FOR CASES 
Helicobacter Pylori Positive Helicobacter Pylori Negative 
51-60 61-70 71-80 41-50 
Controls 
10-20 21-30 31-40 
 
 
 
 
 
AGE GROUP DISTRIBUTION OF 
CHART FOR CONTROLS 
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 There is a male predominance of Helicobacter pylori prevalence 
when compared to females in control group who have normal upper 
gastrointestinal tract (35% Vs 20%). 
 
 
But there is no similar sex predilection in the prevalence of 
Helicobacter pylori in duodenal ulcer patients (77% Vs 80%). 
 
 
Table No. 13 
 
HELICOBACTER PYLORI AND SEX INCIDENCE 
 
 
 
Study Group 
Helicobacter pylori 
 
Positive 
Helicobacter pylori 
 
Negative 
M % F % M % F % 
Duodenal ulcer 27 77 12 80 8 23 3 20 
Control 7 35 6 20 13 65 24 80 
 HELICOBACTER PYLORI DURATION OF ILLNESS 
 
The prevalence of Helicobacter pylori increased with chronicity 
of symptoms and duration of illness. 
Table No. 14 
 
Duration of 
 
Illness 
No. of 
 
Patients 
Helicobacter pylori Positive 
 
Percentage Positive Negative 
< 6 months 14 9 5 64 
6 months - 1 yr 26 20 6 77 
1 - 2 yr 6 6 0 100 
> 2 yr 4 4 0 100 
 71-80 > 2 yrs 1 - 2 yrs <6 months 6 months - 1 
yr 
 
 
 
 
 
HELICOBACTER PYLORI AND 
DURATION OF ILLNESS 
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                 DISCUSSION  
AND COMPARATIVE ANALYSIS 

Helicobacter pylori and non steroidal anti-inflammatory drugs 
have been considered as two major etiological agents in peptic ulcer 
disease and acid remains as a contribution than a prime cause56. 
The maxim “once an ulcer, always an ulcer” is no longer 
appropriate after the discovery of Helicobacter pylori. 
 
 
This study is intended to find out the relation between 
Helicobacter pylori and duodenal ulcer and to correlate and compare 
with other studies. 
This study shows that the prevalence of Helicobacter pylori in 
duodenal ulcer patients is 78% which is correlated with other studies 
below. 
 
 
The prevalence of Helicobacter pylori in normal gastrointestinal 
tract is 26%. In most of the western studies the prevalence is ranging 
between 0-255. 
 Indian study by Prabhu et al showed a prevalence of 23.5%. 
 
This present study has shown high prevalence of Helicobacter 
pylori in duodenal ulcer patients (78%) than in normal upper 
gastrointestinal tract mucosa (26%). There is a definite relationship 
between Helicobacter pylori and duodenal ulcer. 
Table No.15 
 
 
Name of study 
Year of 
study 
Patients with duodenal ulcer 
No. of 
Patients 
Helicobacter 
pylori positive % 
Marshall and Warren 1984 13 100 
Langenberg et al 1984 9 100 
Burnett et al 1984 7 57 
Lambert et al 1985 61 95 
Mc Nulty and Watson 1986 20 95 
Booth et al 1986 25 78 
Von Wulffen et al 1986 54 83 
Pettross et al 1986 25 60 
Humphries et al 1986 64 93 
Lamouliatte et al 1986 21 90 
Fiocca et al 1987 30 88 
Hirchl et al 1987 53 98 
Graham et al 1987 85 91 
Rauws and Tytgat57 1989 165 100 
Present Study 2006 50 78 
 Table No. 16 
 
 
Name of study 
 
Year of 
study 
Patients with duodenal ulcer 
No. of 
Patients 
Helicobacter pylori 
positive % 
Forrest et al 1984 25 24 
Jones et al 1984 15 0 
Langenberg et al 1984 19 5 
Meyrick Thomal et al 1984 9 0 
Rollason et al 1984 10 10 
Lambert et al 1985 21 5 
Buck et al 1986 7 14 
Jiang et al 1987 15 20 
Raskov et al 1987 50 20 
Johnson et al 1988 105 10 
Prabhu et al (Indian) 1993 17 23.5 
Present Study 2006 50 26 
 
The prevalence rate of helicobacter pylori increases progressively 
with age62. Several studies show that it is  10-20  in young adults, 50% 
between 50-60 yrs and increases to 75% over 65  yrs of age62. 
 Our study has well correlated with the above fact that it shows 
increasing prevalence with age in patients with duodenal ulcer. 
 
 
In the present study the prevalence of helicobacter pylori infection 
is almost double in males when compared to females in those with 
normal upper gastrointestinal tract. 
 
 
This correlates with the fact that helicobacter pylori infection is  a 
male preponderance disease. Certain studies are available to support this. 
A study conducted in rural Columbian andes communities found higher 
incidence of infection rates in young males59. A birth cohort of 
21 year olds in Newzealand revealed a higher seropositivity  in  males60. 
Males in a variety of ethnic groups in California had higher 
seropositivity than females61. 
 
In duodenal ulcer patients the prevalence is almost equal in both 
male and female. 
 
 
The prevalence of helicobacter pylori increased with chronicity of 
the disease. 
 But this cannot be considered very significant because the patients 
above 1-2 yrs duration is a very small group when compared with 
patients who have lesser duration disease. It may  require  a  bigger 
sample and equal number of patient in both groups to compare. 
 
 
The various symptoms were analysed in relation to prevalence  of 
helicobacter pylori. 
 
 
The most common and prominent symptom is abdominal pain and 
periodicity. 
Abdominal pain is present in almost all patients. 
 
 
 
Periodicity is present in 87% of cases in whom the rapid urease 
test  was  +ve  when  compared  to  72% in whom rapid urease test   was 
-ve. 
 
 
The next common symptom was nocturnal pain. It was present  in 
64% of patients with helicobacter pylori positive when compared to 55% 
of patients with helicobacter pylori negative. 
 Other symptoms include G.I. bleed and retrosternal burning 
sensation whose prevalence was 28% and 87% respectively. Water brash 
was present in 38%. 
Table No. 17 
 
 
 
 
 
Symptoms 
Helicobacter pylori 
 
+ve (39) 
Helicobacter pylori 
 
-ve (11) 
No. of 
 
Patients 
 
Percentage 
No. of 
 
Patients 
 
Percentage 
Periodicity 34 87 8 72 
Nocturnal pain 25 64 6 55 
Retrostrenal 
 
burning pain 
34 87 9 82 
Water brash 15 38 3 27 
GI bleeding 11 28 0 0 
 
 
A study conducted at AIIMS - New Delhi in 1980 the nocturnal 
pain was present only in 40% of patients and less than 10% had 
gastrointestinal bleeding. But recently the prevalence  of  nocturnal pain 
seems to be increasing64. 
 This may be because of change in lifestyle with longer working 
hours and increased stress. 
 
 
Although complications are not increased by presence of 
helicobacter pylori is increased in patients developing complications. 
This fact can be used for therapeutic purpose that eradication may reduce 
the further complications. 
 
 
Eradication of helicobacter pylori in uncomplicated ulcers  results 
in higher eradication rates and lower recurrence rate less than 10%. This 
results in lesser complication rate. 
 
 
A combination of rapid urease test and brush cytology was  found 
to be the most sensitive and least expensive test. 
CONCLUSION 

To conclude this study conducted at Department of Surgery, 
Coimbatore Medical College which comprise of 100 patients of whom 
50 has duodenal ulcer and another 50 with normal upper gastrointestinal 
tract to under went upper gastrointestinal tract endoscopy the following 
facts are highlighted. 
 
 
1. This study reveals that rapid urease test is very easy, less 
expensive out patients procedure to diagnose helicobacter pylori 
infection. 
 
 
2. There is a definitive relationship between helicobacter  pylori and 
duodenal ulcer. 
 
 
3. It appears to play a causative role in the pathogenesis of duodenal 
ulcer. 
 
 
4. There is a 78% prevalence of helicobacter pylori in duodenal ulcer 
patients when compared to 26% prevalence in those with normal 
Gastrointestinal tract. 
 5. It also correlated with other studies in the prevalence of 
helicobacter pylori in duodenal ulcer. 
 
 
6. It reveals that the prevalence of helicobacter pylori is doubled in 
males when compared to females in controls. 
 
 
7. But the prevalence is equal in both sexes in duodenal ulcer 
patients. 
 
 
8. It reveals that there is a positive relationship between helicobacter 
pylori and duration of disease. 
 
 
9. It reveals that helicobacter pylori infection increase progressively 
with age. 
 
 
10. Helicobacter pylori prevalence in duodenal ulcer patients can be 
detected by an outpatient procedure (endoscopy) with aid of 
reliable, cheap rapid urease test.  On detection eradication can  be 
done effectively with available drug combinations. This results in 
prevention of complications in duodenal ulcer patients and also 
high cure rate. 
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OESOPHAGUS NORMAL NOT 
 
 
STOMACH NORMAL NOT 
 
 
DUODENUM NORMAL NOT 
 
 
GASTIC OUTLET OBSTRUCTION PRESENT NOT 
 
 
ULCER BLEEDING PRESENT NOT 
 
 
IMPRESSION DU NORMAL 
 
 
RAPID UREASE TEST POSITIVE NEGATIVE 
  
 
 
MASTER CHART  

CASES 
 
 
Sl. 
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Heartburn 
& Acid 
Eructation 
G.I. 
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Goo 
Endo 
scopy 
 
RUT 
Food Antacid Vomiting 
1 Raman 28 / M 1408/05 + 4 mon + + - - - - - - - DU - 
2 Backiam 48 / F 1458/05 + 2 mon - + + - - + + - - DU + 
3 Senthilkumar 18 / M 1518/05 + 6 mon - - - - - - - - - DU - 
4 Siva 31 / M 1526/05 + 3 mon + + + - - + + + - DU + 
5 Ramalingam 44 / M 1534/05 + 11mon + + + - + + + - - DU + 
6 Xavier 26 / M 1603/05 + 7 mon + + - - - - + - - DU + 
7 Bama 33 / F 1679/05 + 2 mon + + - - - + + + - DU + 
8 Kandasamy 53 / M 1681/05 + 10mon + - - - - + + - - DU + 
9 Michael 34 / M 1712/05 + 11mon + + - - - - - - - DU + 
10 Ahmed 73 / M 1741/05 + 7 mon + + - - - - + - - DU + 
11 Sooman 35 / F 1750/05 + 4 mon + + - - - - + + - DU + 
12 Ramasamy 63 / M 1790/05 + 5 mon + + - - - - + - - DU + 
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brash 
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Eructation 
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Endo 
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RUT 
Food Antacid Vomiting 
13 Saravanan 16 / M 1796/05 + 11mon - + + - - - - - - DU - 
14 Kannan 21 / M 1810/05 + 8 mon - + - - + + + + - DU + 
15 Sundaralingam 56 / M 1815/05 + 7 mon + + - - - + + - - DU + 
16 Kanaga 38 / F 1824/05 + 11mon + + - - - - + - - DU + 
17 Ramasamy 41 / M 1844/05 + 7 mon + + - - - - - - - DU + 
18 Ramayee 74 / F 1902/05 + 10mon + - - - - - - - - DU + 
19 Sundaram 36 / M 1905/05 + 5 mon - - - - - +   - DU - 
20 Kumaravel 32 / M 1896/05 + 8 mon + + + - + - + + + DU + 
21 Lakshmi 55 / F 1910/05 + 3 yrs + + - - + - + - - DU + 
22 Jeeva 16 / F 1912/05 + 10mon + + - - - - - - - DU - 
23 Thangam 34 / F 2004/05 + 1½ yrs + - - - - - + + - DU + 
24 Durai 58 / M 2110/05 + 1½ yrs + - + - + - + - + DU + 
25 Karuppasami 38 / M 2118/05 + 4 yrs - - - - + + + - - DU + 
26 Mani 29 / M 2306/05 + 7 mon + + - - - - + - - DU + 
27 Mahalingam 53 / M 2812/05 + 10mon + + + - - - + - - DU + 
28 Fathima 26 / F 2348/05 + 8 mon + - - - - + + - - DU - 
29 Mangalam 36 / F 2566/06 + 2 yrs + - - - - - - - - DU + 
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Endo 
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RUT 
Food Antacid Vomiting 
30 Mani 33 / M 2680/05 + 11mon + - - - - - + - - DU + 
31 Kanagavel 24 / M 2730/05 + 8 mon + + - - - + + - - DU + 
32 Sundaram 38 / M 2840/05 + 5 yrs + + - - - - + + + DU + 
33 Sumathi 38 / F 2936/05 + 7 mon + + + - - - - - - DU - 
34 Lakshmanan 61 / M 2954/05 + 2 yrs + - - - - - + - - DU + 
35 Vairavan 56 / M 3060/05 + 10mon + - - - + - + - - DU + 
36 Suganthi 32 / F 3079/05 + 3 mon - - - - - + + - - DU + 
37 Subbammal 65 / F 90/06 + 1½ yrs + - - - - - + + - DU + 
38 Suresh 18 / M 125/06 + 3 mon - - - - - - + - - DU - 
39 Kanagavel 45 / M 250/06 + 5 mon + - - - - + + - - DU + 
40 Swaminathan 39 / M 270/06 + 2 mon + - - - - - - - - DU - 
41 Gopal 48 / M 282/06 + 9 mon + - - - - + + - - DU - 
42 Ramasamy 32 / M 321/06 + 4 mon - + - - - - + + - DU + 
43 Maran 55 / M 340/06 + 2 yrs + + + - - + + - + DU + 
44 Latha 28 / F 359/06 + 8 mon + + - - - - + - - DU + 
45 Krishnan 49 / M 393/06 + 4 yrs + - - - + - + + + DU + 
46 Xavier 37 / M 420/06 + 9 mon + + - - - - + - - DU + 
  
 
 
 
Sl. 
No. 
 
Name 
Age 
/Sex 
 
IP No. 
 
Pain 
Dura 
tion 
Perio 
dicity 
Noct. 
Pain 
Related to 
Water 
brash 
Heartburn 
& Acid 
Eructation 
G.I. 
Bleed 
 
Goo 
Endo 
scopy 
 
RUT 
Food Antacid Vomiting 
47 Kannan 56 / M 448/06 + 7 mon + - - - - - + + - DU + 
48 Rukmani 30 / F 460/06 + 3 mon + + - - - - + - - DU + 
49 John 41 / M 484/06 + 8 mon + + - - - - - - - DU + 
50 Mahalingam 53 / M 496/06 + 10mon - - - - - - - - - DU - 
  
 
 
CONTROLS 
 
 
 
Sl. No. Name Age / Sex IP No. Endoscopy RUT 
1 Saroja 24 / F 1402/05 N - 
2 Muthusamy 47 / M 1468/05 N - 
3 Ramesh 25 / M 1469/05 N + 
4 Rakkammal 49 / F 1507/05 N - 
5 Jothi 25 / F 1510/05 N - 
6 Manohar 36 / M 1529/05 N - 
7 Suresh 18 / M 1532/05 N - 
8 Lakshmi 46 / F 1606/05 N - 
9 Antony 34 / M 1686/05 N + 
10 Fathima 68 / F 1708/05 N - 
11 Kaliammal 39 / F 1744/05 N - 
12 Angammal 56 / F 1755/05 N - 
13 Subramani 42 / M 1794/05 N - 
  
 
 
 
Sl. No. Name Age / Sex IP No. Endoscopy RUT 
14 Cellammal 36 / F 1808/05 N + 
15 Mariappan 32 / M 1812/05 N - 
16 Thangamani 58 / F 1822/05 N - 
17 Selvi 29 / F 1840/05 N - 
18 Kannan 36 / M 1898/05 N - 
19 Mariyayee 32 / F 1906/05 N + 
20 Mani 24 / M 1914/05 N - 
21 Vasantha 46 / F 2010/05 N - 
22 Akbar 38 / M 2004/05 N - 
23 Chellammal 40 / F 2120/05 N + 
24 Dhanalakshmi 36 / F 2301/05 N - 
25 Rajeswari 49 / F 2309/05 N + 
26 Gokila 20 / F 2340/05 N - 
27 Shantha 35 / F 2344/05 N - 
28 Sangappan 64 / M 2564/05 N + 
  
 
 
 
Sl. No. Name Age / Sex IP No. Endoscopy RUT 
29 Mary 47 / F 2674/05 N - 
30 Devi 16 / F 2682/05 N - 
31 Veerammal 44 / F 2725/05 N - 
32 Ganesan 32 / M 2734/05 N + 
33 Gowri 33 / F 2844/05 N - 
34 Arumugam 28 / M 2938/05 N - 
35 Raman 38 / M 2961/05 N + 
36 Mohammed Ismail 71 / M 3055/05 N - 
37 Gunasamy 44 / M 3088/05 N + 
38 Umarani 22 / F 84/06 N - 
39 Jeevanandham 34 / M 123/06 N - 
40 Sivabackiam 53 / F 241/06 N - 
41 Subbulakshmi 46 / F 244/06 N + 
42 Hanifa 74 / M 268/06 N - 
43 Devi 26 / F 279/06 N - 
  
 
 
 
Sl. No. Name Age / Sex IP No. Endoscopy RUT 
44 Parvathy 55 / F 323/06 N + 
45 Lakshmi 43 / F 344/06 N - 
46 Radha 27 / F 361/06 N - 
47 Mani 42 / M 394/06 N + 
48 Kaliammal 44 / F 424/06 N - 
49 Ganesh 26 / M 453/06 N - 
50 Sundarammal 36 / F 464/06 N - 
 
